Oliver Van Oekelen: First Targeted/Personalized Treatment for CAR⁺ T-Cell Lymphoma
Oliver Van Oekelen, Hematology/Medical Oncology Fellow at Icahn School of Medicine at Mount Sinai, shared on LinkedIn about a recent paper by Adolfo Aleman et al. published on NEJM:
“Excited to share that our case report has just been published in the New England Journal of Medicine!
As co–first author, I had the privilege of working with an incredible team at the Icahn School of Medicine at Mount Sinai: the first targeted/personalized treatment of a CAR⁺ T-cell lymphoma that developed after anti-BCMA CAR T-cell therapy for multiple myeloma.
Using rapid molecular profiling and repurposing of an FDA-approved immunotherapy, we were able to eradicate the secondary malignancy. Remarkably, the patient is now in remission from both cancers.
This case highlights both the promise and complexity of cellular immunotherapy. While CAR T cells have transformed outcomes in multiple myeloma, rare but serious complications like secondary T-cell lymphomas can arise. Our work demonstrates how precision medicine and adaptive thinking can turn a high-risk scenario into a success story.
I am deeply grateful to my co–first author Dr. Adolfo Aleman, senior author Dr. Samir Parekh, and the multidisciplinary team spanning immunology, pathology, genomics, dermatology, and clinical oncology, who made this possible.
A special thanks to the NIH R38 StARR program, which supported my training in translational research and allowed me to pursue this work at the intersection of clinical care and laboratory discovery. I also received support from the American Society of Hematology HONORS program.
Proud to contribute to research that not only advances our understanding of CAR T-cell therapy but also underscores the power of collaboration in tackling the toughest challenges in hematology/oncology.”
Title: Targeted Therapy of CAR+ T-Cell Lymphoma after Anti-BCMA CAR T-Cell Therapy
Authors: Adolfo Aleman, Oliver Van Oekelen, David T. Melnekoff, Leah Grossman, Tarek H. Mouhieddine, Agata Kurowski, Ivan Odak, Sidorela Reci, Shriya Desai, Shannon Meledathu, Malini P. Naidu, Ravi P. Shukla, Rudra P. Dutta, Katerina Kappes, Kseniya Serebryakova, Hayley Jackson, Jordan Lu, Anastasia Chatikhine, Raksha Kulkarni, Zahra Moinfar, Matthew M. Croken, Meenakshi Mehrotra, Brett Baskovich, Sampanna Rayamajhi, Shambavi Richard, Adriana C. Rossi, Christian Salib, Jane Houldsworth, Brian D. Brown, Miriam Merad, Alessandro Laganà, Patrick M. Brunner, Sundar Jagannath, Joshua D. Brody, Samir Parekh.
Other posts featuring Oliver Van Oekelen.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023